Isa Mohamed Rose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isa Mohamed Rose has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Rahman Jamal
UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
3 shared publications - Zairul Azwan Mohd Azman
Department of Surgery, Faculty of Medicine, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
3 shared publications - Ismail Sagap
Department of Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia
2 shared publications - Luqman Mazlan
Department of Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia
2 shared publications - Muhiddin Ishak
UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia
2 shared publications - Norfilza Mohd Mokhtar
Research Management Centre, Management and Science University (MSU), Selangor, Malaysia
2 shared publications
Latest Publications
- Open Access
TCGA-My: A Systematic Repository for Systems Biology of Malaysian Colorectal Cancer
Colorectal cancer (CRC) ranks second among the most commonly occurring cancers in Malaysia, and unfortunately, its pathobiology remains unknown. CRC pathobiology can be understood in detail with the implementation of omics technology that is able to generate vast amounts of molecular data. The generation of omics data has introduced a new challenge for data organization. Therefore, a knowledge-based repository, namely TCGA-My, was developed to systematically store and organize CRC omics data for Malaysian patients. TCGA-My stores the genome and metabolome of Malaysian CRC patients. The genome and metabolome datasets were organized using a Python module, pandas. The variants and metabolites were first annotated with their biological information using gene ontologies (GOs) vocabulary. The TCGA-My relational database was then built using HeidiSQL PorTable 9.4.0.512, and Laravel was used to design the web interface. Currently, TCGA-My stores 1,517,841 variants, 23,695 genes, and 167,451 metabolites from the samples of 50 CRC patients. Data entries can be accessed via search and browse menus. TCGA-My aims to offer effective and systematic omics data management, allowing it to become the main resource for Malaysian CRC research, particularly in the context of biomarker identification for precision medicine.
Open AccessTCGA-My: A Systematic Repository for Systems Biology of Malaysian Colorectal Cancer
Colorectal cancer (CRC) ranks second among the most commonly occurring cancers in Malaysia, and unfortunately, its pathobiology remains unknown. CRC pathobiology can be understood in detail with the implementation of omics technology that is able to generate vast amounts of molecular data. The generation of omics data has introduced a new challenge for data organization. Therefore, a knowledge-based repository, namely TCGA-My, was developed to systematically store and organize CRC omics data for Malaysian patients. TCGA-My stores the genome and metabolome of Malaysian CRC patients. The genome and metabolome datasets were organized using a Python module, pandas. The variants and metabolites were first annotated with their biological information using gene ontologies (GOs) vocabulary. The TCGA-My relational database was then built using HeidiSQL PorTable 9.4.0.512, and Laravel was used to design the web interface. Currently, TCGA-My stores 1,517,841 variants, 23,695 genes, and 167,451 metabolites from the samples of 50 CRC patients. Data entries can be accessed via search and browse menus. TCGA-My aims to offer effective and systematic omics data management, allowing it to become the main resource for Malaysian CRC research, particularly in the context of biomarker identification for precision medicine.
- Open Access
- 5 May 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (5) , 719
Genome-Wide Open Chromatin Methylome Profiles in Colorectal Cancer
The methylome of open chromatins was investigated in colorectal cancer (CRC) to explore cancer-specific methylation and potential biomarkers. Epigenome-wide methylome of open chromatins was studied in colorectal cancer tissues using the Infinium DNA MethylationEPIC assay. Differentially methylated regions were identified using the ChAMP Bioconductor. Our stringent analysis led to the discovery of 2187 significant differentially methylated open chromatins in CRCs. More hypomethylated probes were observed and the trend was similar across all chromosomes. The majority of hyper- and hypomethylated probes in open chromatin were in chromosome 1. Our unsupervised hierarchical clustering analysis showed that 40 significant differentially methylated open chromatins were able to segregate CRC from normal colonic tissues. Receiver operating characteristic analyses from the top 40 probes revealed several significant, highly discriminative, specific and sensitive probes such as OPLAH cg26256223, EYA4 cg01328892, and CCNA1 cg11513637, among others. OPLAH cg26256223 hypermethylation is associated with reduced gene expression in the CRC. This study reports many open chromatin loci with novel differential methylation statuses, some of which with the potential as candidate markers for diagnostic purposes.
- 5 May 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (5) , 719
Open AccessGenome-Wide Open Chromatin Methylome Profiles in Colorectal Cancer
The methylome of open chromatins was investigated in colorectal cancer (CRC) to explore cancer-specific methylation and potential biomarkers. Epigenome-wide methylome of open chromatins was studied in colorectal cancer tissues using the Infinium DNA MethylationEPIC assay. Differentially methylated regions were identified using the ChAMP Bioconductor. Our stringent analysis led to the discovery of 2187 significant differentially methylated open chromatins in CRCs. More hypomethylated probes were observed and the trend was similar across all chromosomes. The majority of hyper- and hypomethylated probes in open chromatin were in chromosome 1. Our unsupervised hierarchical clustering analysis showed that 40 significant differentially methylated open chromatins were able to segregate CRC from normal colonic tissues. Receiver operating characteristic analyses from the top 40 probes revealed several significant, highly discriminative, specific and sensitive probes such as OPLAH cg26256223, EYA4 cg01328892, and CCNA1 cg11513637, among others. OPLAH cg26256223 hypermethylation is associated with reduced gene expression in the CRC. This study reports many open chromatin loci with novel differential methylation statuses, some of which with the potential as candidate markers for diagnostic purposes.
- Open Access
- 13 June 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (S4) , 550
A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia
Inflammatory bowel disease (IBD) was once considered as a Western disease. However, recent epidemiological data showed an emerging trend of IBD cases in the Eastern Asia countries. Clinico-epidemiological data of IBD in Malaysia is scarce. This study aimed to address this issue. Retrospective analysis of ulcerative colitis (UC) and Crohn’s disease (CD), diagnosed from January 1980 till June 2018 was conducted at our centre. A total of 413 IBD patients (281 UC, 132 CD) were identified. Mean crude incidence of IBD has increased steadily over the first three decades: 0.36 (1980–1989), 0.48 (1990–1999) and 0.63 per 100,000 person-years (2000–2009). In the 2010 to 2018 period, the mean crude incidence has doubled to 1.46 per 100,000 person-years. There was a significant rise in the incidence of CD, as depicted by reducing UC:CD ratio: 5:1 (1980–1989), 5:1 (1990–1999), 1.9:1 (2000–2009) and 1.7:1 (2010–2018). The prevalence rate of IBD, UC and CD, respectively were 23.0, 15.67 and 7.36 per 100,000 persons. Of all IBD patients, 61.5% (n = 254) were males. When stratified according to ethnic group, the highest prevalence of IBD was among the Indians: 73.4 per 100,000 persons, followed by Malays: 24.8 per 100,000 persons and Chinese: 14.6 per 100,000 persons. The mean age of diagnosis was 41.2 years for UC and 27.4 years for CD. Majority were non-smokers (UC: 76.9%, CD: 70.5%). The diseases were classified as follows: UC; proctitis (9.2%), left-sided colitis (50.2%) and extensive colitis (40.6%), CD; isolated ileal (22.7%), colonic (28.8%), ileocolonic (47.7%) and upper gastrointestinal (0.8%). 12.9% of CD patients had concurrent perianal disease. Extra intestinal manifestations were observed more in CD (53.8%) as compared to UC (12%). Dysplasia and malignancy, on the other hand, occurred more in UC (4.3%, n = 12) than in CD (0.8%, n = 1). Over one quarter (27.3%) of CD patients and 3.6% of UC patients received biologic therapy. The incidence of IBD is rising in Malaysia, especially in the last one decade. This might be associated with the urbanization and changing diets. Public and clinicians’ awareness of this emerging disease in Malaysia is important for the timely detection and management.
- 13 June 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (S4) , 550
Open AccessA four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia
Inflammatory bowel disease (IBD) was once considered as a Western disease. However, recent epidemiological data showed an emerging trend of IBD cases in the Eastern Asia countries. Clinico-epidemiological data of IBD in Malaysia is scarce. This study aimed to address this issue. Retrospective analysis of ulcerative colitis (UC) and Crohn’s disease (CD), diagnosed from January 1980 till June 2018 was conducted at our centre. A total of 413 IBD patients (281 UC, 132 CD) were identified. Mean crude incidence of IBD has increased steadily over the first three decades: 0.36 (1980–1989), 0.48 (1990–1999) and 0.63 per 100,000 person-years (2000–2009). In the 2010 to 2018 period, the mean crude incidence has doubled to 1.46 per 100,000 person-years. There was a significant rise in the incidence of CD, as depicted by reducing UC:CD ratio: 5:1 (1980–1989), 5:1 (1990–1999), 1.9:1 (2000–2009) and 1.7:1 (2010–2018). The prevalence rate of IBD, UC and CD, respectively were 23.0, 15.67 and 7.36 per 100,000 persons. Of all IBD patients, 61.5% (n = 254) were males. When stratified according to ethnic group, the highest prevalence of IBD was among the Indians: 73.4 per 100,000 persons, followed by Malays: 24.8 per 100,000 persons and Chinese: 14.6 per 100,000 persons. The mean age of diagnosis was 41.2 years for UC and 27.4 years for CD. Majority were non-smokers (UC: 76.9%, CD: 70.5%). The diseases were classified as follows: UC; proctitis (9.2%), left-sided colitis (50.2%) and extensive colitis (40.6%), CD; isolated ileal (22.7%), colonic (28.8%), ileocolonic (47.7%) and upper gastrointestinal (0.8%). 12.9% of CD patients had concurrent perianal disease. Extra intestinal manifestations were observed more in CD (53.8%) as compared to UC (12%). Dysplasia and malignancy, on the other hand, occurred more in UC (4.3%, n = 12) than in CD (0.8%, n = 1). Over one quarter (27.3%) of CD patients and 3.6% of UC patients received biologic therapy. The incidence of IBD is rising in Malaysia, especially in the last one decade. This might be associated with the urbanization and changing diets. Public and clinicians’ awareness of this emerging disease in Malaysia is important for the timely detection and management.
- Open Access
- 1 February 2019
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 20 (2) , 509-517
Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer
Introduction: Microsatellite instability (MSI) is a hallmark of defective DNA mismatch repair (MMR) of genesespecially MLH1 and MSH2. It is frequently involved in the carcinogenesis of various tumours including gastriccancer (GC). However, MSI in GCs have not been reported in Malaysia before. Objective: This study was conductedto determine the microsatellite instability (MSI) status in gastric cancer by microsatellite analysis, sequencing, itsassociation with MLH1 and MSH2 protein expression and H.pylori infection by immunohistochemistry. Method:A total of 60 gastric cancer cases were retrieved. DNA was extracted from paired normal and tumour tissues whileMLH1 and MSH2 protein expression as well as H. pylori status were determined by IHC staining. For microsatelliteanalysis, polymerase chain reaction (PCR) was performed for paired tissue samples using a panel of five microsatellitemarkers. MSI-positive results were subjected for DNA sequencing to assess mutations in the MLH1 and MSH2 genes.Results: Microsatellite analysis identified ten MSI positive cases (16.7%), out of which only six cases (10.3%) showedabsence of MLH1 (n=3) or MSH2 (n=3) protein expression by IHC. The most frequent microsatellite marker in MSIpositive cases was BAT26 (90%). Nine of ten MSI positive cases were intestinal type with one diffuse and all werelocated distally. H. pylori infection was detected in 13 of 60 cases (21.7%) including in three MSI positive cases. Allthese results however were not statistically significant. Our sequencing data displayed novel mutations. However thesedata were not statistically correlated with expression levels of MLH1 and MSH2 proteins by IHC. This may be dueto small sample size to detect small or moderately sized effects. Conclusion: The frequency of MSI in this study wascomparable with published results. Determination of affected MMR genes by more than two antibodies may increasethe sensitivity of IHC to that of MSI analysis.
- 1 February 2019
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 20 (2) , 509-517
Open AccessMicrosatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer
Introduction: Microsatellite instability (MSI) is a hallmark of defective DNA mismatch repair (MMR) of genesespecially MLH1 and MSH2. It is frequently involved in the carcinogenesis of various tumours including gastriccancer (GC). However, MSI in GCs have not been reported in Malaysia before. Objective: This study was conductedto determine the microsatellite instability (MSI) status in gastric cancer by microsatellite analysis, sequencing, itsassociation with MLH1 and MSH2 protein expression and H.pylori infection by immunohistochemistry. Method:A total of 60 gastric cancer cases were retrieved. DNA was extracted from paired normal and tumour tissues whileMLH1 and MSH2 protein expression as well as H. pylori status were determined by IHC staining. For microsatelliteanalysis, polymerase chain reaction (PCR) was performed for paired tissue samples using a panel of five microsatellitemarkers. MSI-positive results were subjected for DNA sequencing to assess mutations in the MLH1 and MSH2 genes.Results: Microsatellite analysis identified ten MSI positive cases (16.7%), out of which only six cases (10.3%) showedabsence of MLH1 (n=3) or MSH2 (n=3) protein expression by IHC. The most frequent microsatellite marker in MSIpositive cases was BAT26 (90%). Nine of ten MSI positive cases were intestinal type with one diffuse and all werelocated distally. H. pylori infection was detected in 13 of 60 cases (21.7%) including in three MSI positive cases. Allthese results however were not statistically significant. Our sequencing data displayed novel mutations. However thesedata were not statistically correlated with expression levels of MLH1 and MSH2 proteins by IHC. This may be dueto small sample size to detect small or moderately sized effects. Conclusion: The frequency of MSI in this study wascomparable with published results. Determination of affected MMR genes by more than two antibodies may increasethe sensitivity of IHC to that of MSI analysis.
- Open Access
- 8 September 2016
- Published by Springer Nature in BMC Medical Genomics
- Vol. 9 (1) , 1-13
A 19-Gene expression signature as a predictor of survival in colorectal cancer
Histopathological assessment has a low potential to predict clinical outcome in patients with the same stage of colorectal cancer. More specific and sensitive biomarkers to determine patients’ survival are needed. We aimed to determine gene expression signatures as reliable prognostic marker that could predict survival of colorectal cancer patients with Dukes’ B and C. We examined microarray gene expression profiles of 78 archived tissues of patients with Dukes’ B and C using the Illumina DASL assay. The gene expression data were analyzed using the GeneSpring software and R programming. The outliers were detected and replaced with randomly chosen genes from the 90 % confidence interval of the robust mean for each group. We performed three statistical methods (SAM, LIMMA and t-test) to identify significant genes. There were 19 significant common genes identified from microarray data that have been permutated 100 times namely NOTCH2, ITPRIP, FRMD6, GFRA4, OSBPL9, CPXCR1, SORCS2, PDC, C12orf66, SLC38A9, OR10H5, TRIP13, MRPL52, DUSP21, BRCA1, ELTD1, SPG7, LASS6 and DUOX2. This 19-gene signature was able to significantly predict the survival of patients with colorectal cancer compared to the conventional Dukes’ classification in both training and test sets (p < 0.05). The performance of this signature was further validated as a significant independent predictor of survival using patient cohorts from Australia (n = 185), USA (n = 114), Denmark (n = 37) and Norway (n = 95) (p < 0.05). Validation using quantitative PCR confirmed similar expression pattern for the six selected genes. Profiling of these 19 genes may provide a more accurate method to predict survival of patients with colorectal cancer and assist in identifying patients who require more intensive treatment.
- 8 September 2016
- Published by Springer Nature in BMC Medical Genomics
- Vol. 9 (1) , 1-13
Open AccessA 19-Gene expression signature as a predictor of survival in colorectal cancer
Histopathological assessment has a low potential to predict clinical outcome in patients with the same stage of colorectal cancer. More specific and sensitive biomarkers to determine patients’ survival are needed. We aimed to determine gene expression signatures as reliable prognostic marker that could predict survival of colorectal cancer patients with Dukes’ B and C. We examined microarray gene expression profiles of 78 archived tissues of patients with Dukes’ B and C using the Illumina DASL assay. The gene expression data were analyzed using the GeneSpring software and R programming. The outliers were detected and replaced with randomly chosen genes from the 90 % confidence interval of the robust mean for each group. We performed three statistical methods (SAM, LIMMA and t-test) to identify significant genes. There were 19 significant common genes identified from microarray data that have been permutated 100 times namely NOTCH2, ITPRIP, FRMD6, GFRA4, OSBPL9, CPXCR1, SORCS2, PDC, C12orf66, SLC38A9, OR10H5, TRIP13, MRPL52, DUSP21, BRCA1, ELTD1, SPG7, LASS6 and DUOX2. This 19-gene signature was able to significantly predict the survival of patients with colorectal cancer compared to the conventional Dukes’ classification in both training and test sets (p < 0.05). The performance of this signature was further validated as a significant independent predictor of survival using patient cohorts from Australia (n = 185), USA (n = 114), Denmark (n = 37) and Norway (n = 95) (p < 0.05). Validation using quantitative PCR confirmed similar expression pattern for the six selected genes. Profiling of these 19 genes may provide a more accurate method to predict survival of patients with colorectal cancer and assist in identifying patients who require more intensive treatment.